← All trials
NCT02369549
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2015
- Primary completion
- Apr 1, 2018
- Completion date
- Dec 1, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 750
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- University of Western OntarioLead sponsor
- The Kidney Foundation of CanadaCollaborator
- Canadian Institutes of Health Research (CIHR)Collaborator
- University of Western OntarioOverall official - principal investigator
- University of Western OntarioReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.